CAPSOVISION INC
CVNASDAQTrading Snapshot
- Day Range
- $6.64 – $6.82
- 52-Week Range
- $4.38 – $15.37
- Volume
- $1.90B
- Avg Volume
- $2.53B
- Shares Outstanding
- 50.0M
- Next Earnings
- Dec 3, 2026
Fundamentals Snapshot
- Annual Revenue
- $14M
- Last Q Revenue
- $4M
- P/E Ratio
- -11.0
- P/S Ratio
- 24.9x
- EPS (TTM)
- $-0.60
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +1.1%
Why Investors Own CV
- ✓High-growth profile — revenue up +41.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 57% gross margin and 8% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CAPSOVISION INC
CV
StockOtter · stockotter.spaceAbout CAPSOVISION INC
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV CongressPR Newsw
CapsoVision gets FDA clearance for AI Highlights
What happened CapsoVision, Inc. (NASDAQ: CV) said AI Highlights, its AI-assisted reading tool for CapsoCam Plus, received FDA clearance on September 25, 2026. The company says it is a commercial-stage medical technology
CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus®
AI-assisted reading tool designed to aid physician review of small bowel capsule endoscopy studies performed due to suspected bleeding using the CapsoCam Plus® system AI-assisted reading tool designed to aid physician re
CapsoVision (NASDAQ:CV) Major Shareholder Eliyahou Et Al Harari Purchases 1,757,469 Shares
CapsoVision, Inc. (NASDAQ: CV - Get Free Report) major shareholder Eliyahou Et Al Harari acquired 1,757,469 shares of CapsoVision stock in a transaction that occurred on Friday, September 18th. The shares were purchased
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis
AbbVie Announces European Commission Approval of RINVOQÂ (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic ArthritisPR
Critical Contrast: Zimmer Biomet (NYSE:ZBH) versus CapsoVision (NASDAQ:CV)
Zimmer Biomet (NYSE: ZBH - Get Free Report) and CapsoVision (NASDAQ: CV - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their r